1 Dragu, D. L., Necula, L. G., Bleotu, C., Diaconu, C. C. & Chivu-Economescu, M. Therapies targeting cancer stem cells: Current trends and future challenges. World journal of stem cells7, 1185 (2015).
2 Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes & development17, 1253-1270 (2003).
3 Kreitman, R. J., Siegall, C. B., Chaudhary, V. K., FitzGerald, D. J. & Pastan, I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor .alpha. at different locations in Pseudomonas exotoxin. Bioconjugate Chemistry3, 63-68, doi:10.1021/bc00013a010 (1992).
4 Candolfi, M. et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences107, 20021-20026 (2010).
5 Kimchi-Sarfaty, C. et al. SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice. Cancer gene therapy13, 648 (2006).
6 McDermott, S. P. & Wicha, M. S. Targeting breast cancer stem cells. Molecular Oncology4, 404-419, doi:http://dx.doi.org/10.1016/j.molonc.2010.06.005 (2010).
7 Todorović-Raković, N. & Milovanović, J. Interleukin-8 in breast cancer progression. Journal of Interferon & Cytokine Research33, 563-570 (2013).
8 Duncan, R., Milburn, S. C. & Hershey, J. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. Journal of Biological Chemistry262, 380-388 (1987).
9 Fang, Y. X. et al. Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting. Molecular biotechnology45, 71-81 (2010).
10 Su, Y., Quan, X., Li, L. & Zhou, J. Computer simulation of DNA condensation by PAMAM dendrimer. Macromolecular Theory and Simulations27, 1700070 (2018).
11 Hu, Y., Liu, C. & Muyldermans, S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Frontiers in immunology8, 1442 (2017).
12 Nikkhoi, S. K., Rahbarizadeh, F., Ahmadvand, D. & Moghimi, S. M. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: in vitro proof-of-concept. European Journal of Pharmaceutical Sciences122, 42-50 (2018).
13 Slamon, D. et al. Human breast cancer: correlation of relapse and. science3798106, 235 (1987).
14 Menard, S. et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Annals of oncology12, S15-S19 (2001).
15 Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707-712 (1989).
16 Korkaya, H. et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling. PLoS Biol7, e1000121 (2009).
17 Magnifico, A. et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clinical Cancer Research15, 2010-2021 (2009).
18 Korkaya, H., Paulson, A., Iovino, F. & Wicha, M. S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene27, 6120-6130 (2008).
19 Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M. & Nielsen, L. K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnology and bioengineering83, 173-180 (2003).
20 Reshadmanesh, A., Rahbarizadeh, F., Ahmadvand, D. & Jafari Iri Sofla, F. Evaluation of cellular and transcriptional targeting of breast cancer stem cells via anti-HER2 nanobody conjugated PAMAM dendrimers. Artificial cells, nanomedicine, and biotechnology46, S105-S115 (2018).
21 Jamnani, F. R. et al. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Experimental cell research318, 1112-1124 (2012).
22 Nikkhoi, S. K., Rahbarizadeh, F. & Ahmadvand, D. Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: new biology and novel targeting systems. Protein Expression and Purification129, 115-121 (2017).
23 Moradian, C. & Rahbarizadeh, F. Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5′ UTR. OncoTargets and therapy12, 8809 (2019).
24 Snyder, S. L. & Sobocinski, P. Z. An improved 2, 4, 6-trinitrobenzenesulfonic acid method for the determination of amines. Analytical biochemistry64, 284-288 (1975).
25 Bailey, P. C. et al. Single-Cell Tracking of Breast Cancer Cells Enables Prediction of Sphere Formation from Early Cell Divisions. iScience8, 29-39 (2018).
26 Wan, X., Li, Z., Ye, H. & Cui, Z. Three-dimensional perfused tumour spheroid model for anti-cancer drug screening. Biotechnology letters38, 1389-1395 (2016).
27 Patra, B., Peng, C., Liao, W., Lee, C. & Tung, Y. (Nature Publishing Group, 2016).
28 Ivanov, D. P. et al. Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres. PloS one9 (2014).
29 Yılmaz, Ö. & Sakarya, S. Is ‘Hanging Drop’a Useful Method to Form Spheroids of Jimt, Mcf-7, T-47d, Bt-474 That are Breast Cancer Cell Lines. Single Cell Biol7, 2 (2018).
30 Fant, K. et al. Effects of PEGylation and acetylation of PAMAM dendrimers on DNA binding, cytotoxicity and in vitro transfection efficiency. Molecular pharmaceutics7, 1734-1746 (2010).
31 Hama, S. et al. Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry. Journal of controlled release206, 67-74 (2015).
32 Desoize, B. & Jardillier, J.-C. Multicellular resistance: a paradigm for clinical resistance? Critical reviews in oncology/hematology36, 193-207 (2000).
33 Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F. & Correia, I. J. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnology and bioengineering116, 206-226 (2019).
34 Mathis, J. M. et al. Cancer‐specific targeting of an adenovirus‐delivered herpes simplex virus thymidine kinase suicide gene using translational control. The Journal of Gene Medicine: A cross‐disciplinary journal for research on the science of gene transfer and its clinical applications8, 1105-1120 (2006).
35 Pettersson, F. et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clinical Cancer Research17, 2874-2884 (2011).
36 Sorrells, D. L. et al. Detection of eIF4E gene amplification in breast cancer by competitive PCR. Annals of surgical oncology5, 232-237 (1998).
37 DeFatta, R. J., Chervenak, R. P. & De Benedetti, A. A cancer gene therapy approach through translational control of a suicide gene. Cancer gene therapy9, 505 (2002).
38 Galateanu, B. et al. Impact of multicellular tumor spheroids as an in vivo‑like tumor model on anticancer drug response. International journal of oncology48, 2295-2302 (2016).
39 Grill, J. et al. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Molecular Therapy6, 609-614 (2002).
40 Carver, K., Ming, X. & Juliano, R. L. Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions. Molecular Therapy-Nucleic Acids3, e153 (2014).